Preclinical News and Research

RSS
Novel antibody improves glucose regulation and reduces fatty liver in obese mice

Novel antibody improves glucose regulation and reduces fatty liver in obese mice

Dynamic light scattering technique may help detect people at risk of cataracts and presbyopia

Dynamic light scattering technique may help detect people at risk of cataracts and presbyopia

New $8.5M research grant aims to address patients affected by severe hemophilia A

New $8.5M research grant aims to address patients affected by severe hemophilia A

Novel drug shows promise in mouse models of human metastatic breast cancer

Novel drug shows promise in mouse models of human metastatic breast cancer

Novoron Bioscience receives NIH grant to study novel therapeutic approach for multiple sclerosis

Novoron Bioscience receives NIH grant to study novel therapeutic approach for multiple sclerosis

Variant signs worldwide exclusive license and development agreement with L&F Research

Variant signs worldwide exclusive license and development agreement with L&F Research

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

Novel drug candidate prevents nerve cell damage in mouse model of Parkinson's disease

Novel drug candidate prevents nerve cell damage in mouse model of Parkinson's disease

Anti-aging Glycopeptide can improve efficacy of cell transplant treatments for diabetes patients

Anti-aging Glycopeptide can improve efficacy of cell transplant treatments for diabetes patients

Oxford medical graduates set up website to support Syrian medical students

Oxford medical graduates set up website to support Syrian medical students

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Study offers new view of how cancer cells transform normal cells through 'metastatic hijacking'

Study offers new view of how cancer cells transform normal cells through 'metastatic hijacking'

Use of tumor-treating fields along with chemotherapy improves survival in patients with brain tumor

Use of tumor-treating fields along with chemotherapy improves survival in patients with brain tumor

Heloise Anne Pereira named 2016 National Academy of Inventors Fellow

Heloise Anne Pereira named 2016 National Academy of Inventors Fellow

Cancer drug may protect kidneys from damage caused by chemotherapy agent cisplatin

Cancer drug may protect kidneys from damage caused by chemotherapy agent cisplatin

Columbia Engineering professor wins grant to study tendon-to-bone integration for rotator cuff repair

Columbia Engineering professor wins grant to study tendon-to-bone integration for rotator cuff repair

Lupuzor may become first non-immunosuppressant therapy for lupus

Lupuzor may become first non-immunosuppressant therapy for lupus

Researchers discover novel way to enhance, restore cancer suppressor activity in B-ALL

Researchers discover novel way to enhance, restore cancer suppressor activity in B-ALL

SLU scientist awarded new $2.2 million NIH grant to develop cure for hepatitis B

SLU scientist awarded new $2.2 million NIH grant to develop cure for hepatitis B

ESSA reports net loss of $11.5 million for year ended September 30, 2015

ESSA reports net loss of $11.5 million for year ended September 30, 2015

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.